Genpact downgraded by JP Morgan with a new price target
$G
Professional Services
Consumer Discretionary
JP Morgan downgraded Genpact from Overweight to Neutral and set a new price target of $50.00 from $55.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/17/2024 | $43.00 → $40.00 | Underweight → Neutral | JP Morgan |
| 1/30/2024 | $40.00 | Neutral | Mizuho |
| 12/15/2023 | $38.00 | Outperform → Neutral | Robert W. Baird |
| 8/22/2023 | $40.00 | Neutral → Underweight | JP Morgan |
| 7/18/2023 | $46.00 → $42.00 | Buy → Neutral | Citigroup |
| 12/15/2022 | $55.00 → $50.00 | Overweight → Neutral | JP Morgan |
| 2/14/2022 | $57.00 → $51.00 | Outperform → Market Perform | Cowen & Co. |
| 1/26/2022 | $54.00 | Hold | Jefferies |
4 - Genpact LTD (0001398659) (Issuer)
4 - Genpact LTD (0001398659) (Issuer)
4 - Genpact LTD (0001398659) (Issuer)
Despite a market rebalancing away from large tech companies, reflected by an over 10% correction in the Roundhill Magnificent Seven ETF (NASDAQ:MAGS) in the past two weeks, the so-called “Magnificent Seven” companies still comprise an outsized portion of the S&P 500. The Data: The Magnificent 7 comprises seven of the largest U.S. technology companies weighted heavily in the SPDR S&P 500 ETF Trust (NYSE:SPY). Apple Inc (NASDAQ:AAPL), 6.93% of the index. Microsoft Corp (NASDAQ:MSFT), 6.66% of the index. NVIDIA Corp (NASDAQ:NVDA), 5.95% of the index. Alphabet Inc (NASDAQ:G) (NASDAQ:GOOGL), 4.45% of the index. Amazon.com Inc (NASDAQ:AMZN), 3.94% of the index. Meta Platforms
Ratings for Genpact (NYSE:G) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 4 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 3 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.2, a high estimate of $40.00, and a low estimate of $33.00. This current average has decreased by 3.63% from the previous aver
JP Morgan analyst Tien-Tsin Huang upgrades Genpact (NYSE:G) from Underweight to Neutral and lowers the price target from $43 to $40.
10-Q - Genpact LTD (0001398659) (Filer)
8-K - Genpact LTD (0001398659) (Filer)
10-Q - Genpact LTD (0001398659) (Filer)
Strategic business development leader Jinsook Han joins Genpact to spearhead strategy and M&A NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that Jinsook Han has joined the Company as Chief Strategy and Corporate Development Officer, effective immediately. She will be responsible for the company's strategy and investments, including ventures and acquisitions. Jinsook will report to President and CEO, Balkrishan "BK" Kalra. "Jinsook has that rare profile that
Seasoned technologist joins Genpact to accelerate AI and advanced technology roadmaps NEW YORK, Aug. 7, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that Sanjeev Vohra has been named as the Company's first Chief Technology & Innovation Officer, effective immediately. Vohra will report to President and CEO, Balkrishan "BK" Kalra. Vohra, a seasoned leader and respected innovator, brings more than 30 years of technology, consulting and industry expertise to Genpact. His appointm
NEW YORK, Aug. 5, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that Nicholas "Nick" Gangestad, Senior Vice President and Chief Financial Officer at Rockwell Automation, has been appointed to the Company's Board of Directors, effective August 12th, 2024. Gangestad will serve on the Board's Audit Committee. "Nick's deep expertise in finance and financial operations will not only provide additional insights to our Board, but will also give us valuable, first-hand perspectives on
Total Revenue of $1.21 billion, Up 7% (7% constant currency)1 Diluted EPS of $0.74, Up 16%; Adjusted Diluted EPS2 of $0.85, Up 12% NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Genpact Limited (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced financial results for the third quarter ended September 30, 2024. "We delivered strong results again this quarter, with accelerating revenue growth, driven primarily by client trust in our ability to innovate across Data, Tech and AI. As a result, we are increasing guidance wit
VANCOUVER, BC, Oct. 31, 2024 /CNW/ - Greenlane Renewables Inc. ("Greenlane") (TSX:GRN) (FSE: 52G) intends to announce its 2024 third quarter financial results on Thursday, November 7, 2024 after markets close, followed by a conference call at 5:00 PM ET (2:00 PM PT). Representing management will be Brad Douville, Chief Executive Officer, and Monty Balderston, Chief Financial Officer. A question and answer period with analysts will follow brief remarks from management. Live Conference CallThe public is invited to listen to the conference call in real time by telephone. To acce
NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Genpact Limited (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that its board of directors has declared a cash dividend of $0.1525 per common share for the fourth quarter of 2024. The dividend is payable on December 23, 2024 to shareholders of record as of the close of business on December 9, 2024. The declaration of any future dividends will be at the discretion of the board of directors. About Genpact Genpact (NYSE:G) is a global professional services and solutions
Renewed multi-year partnership to support Ferring Pharmaceuticals' operations in response to rapid business growth NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced the extension of its partnership with Ferring Pharmaceuticals, a research-driven biopharmaceutical company that has operating subsidiaries in more than 50 countries and markets its medicines in over 100 countries. The renewed multi-year agreement will continue the transformation of Ferring's finance, accounting, and procurement operations with advanced technologies, including AI.
Fourth consecutive year of recognition highlights Genpact's expertise in sourcing and procurement, strong partner ecosystem, and advanced technology capabilities driving transformation for clients worldwide NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced that it has been named a Leader for the fourth consecutive year in the 2024 Everest Group Procurement Outsourcing (PO) Services PEAK Matrix® Assessment. This recognition underscores Genpact's excellence in source-to-pay (S2P) services, as well as its innovation in advanced technologies including generative AI, and its partn
Recognition is a testament to Genpact's commitment to positive employee experience and engagement, and its culture of learning and innovation NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, today announced its inclusion on the Forbes list of World's Best Employers 2024 for the fourth consecutive year. Genpact's inclusion on this list is a testament to its dedication to creating a positive and inclusive workplace culture that fosters employee engagement, well-being, continuous learning, and career growth.
SC 13G/A - Genpact LTD (0001398659) (Subject)
SC 13G/A - Genpact LTD (0001398659) (Subject)
SC 13G/A - Genpact LTD (0001398659) (Subject)
JP Morgan upgraded Genpact from Underweight to Neutral and set a new price target of $40.00 from $43.00 previously
Mizuho initiated coverage of Genpact with a rating of Neutral and set a new price target of $40.00
Robert W. Baird downgraded Genpact from Outperform to Neutral and set a new price target of $38.00